Xtant Medical Holdings, Inc.

XTNT · NYSE American · Stock · Healthcare
$0.32
-0.78% today
Delayed price,

What Xtant Medical Holdings does

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.

Key facts

Sector
Healthcare
Industry
Medical Devices
Market cap
$44.3M
P/E (ttm)
—
Forward P/E
-10.5
Dividend yield
0.00%
Beta
-0.20
Profit margin
-10.2%
Employees
151
Headquarters
Belgrade, MT, United States
Exchange
NYSE American

Performance

1 Month
-1.3%
3 Months
-29.8%
6 Months
-34.2%
1 Year
-55.5%
5 Years
-54.9%
$0.2752-week range$0.95
Biggest setback — last 12 months
-64.8%
27 Oct 2025 → 10 Aug 2026
Fell from $0.88 to $0.31 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+32.2%
24 Nov 2025 → 22 Dec 2025
Ran from $0.59 to $0.78 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▼ Trend: Downtrend
Price is below its 20-, 50- and 200-day averages, each stacked below the next — a classic technical downtrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$0.25 (-19.8%)$0.32$0.39 (+24.7%)
3 Months$0.22 (-31.7%)$0.32$0.46 (+46.5%)
6 Months$0.18 (-41.7%)$0.32$0.54 (+71.6%)
12 Months$0.15 (-53.4%)$0.32$0.68 (+114.7%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 76.4%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Acquired 215,517 shares — Lipschultz Tyler, Director · 2026-08-18
Acquired 215,517 shares — BAKEWELL JOHN K, Director · 2026-08-18
Acquired 215,517 shares — Beeson Jonn R., Director · 2026-08-18
Acquired 215,517 shares — JAIN ABHINAV, Director · 2026-08-18
Acquired 323,275 shares — Vizirgianakis Stavros G., Director · 2026-08-18
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.